The valuation gap is striking: Stride's EV/EBITDA of 5.42x represents a roughly 40–60% discount to every peer in the comparable set, from Perdoceo at 8.52x to Graham Holdings at 15.70x. However, the 0.33 PEG ratio may be flattered by a TTM earnings base that has not yet fully reflected the recent $0.46 EPS miss and absent forward guidance. Investors should consider whether the discount reflects a rational repricing of growth durability or an overcorrection that assumes structural rather than cyclical margin compression.

The gross margin trajectory is the most concerning signal: after peaking at 41.1% in 2026Q2, every subsequent quarter has deteriorated or partially recovered without reclaiming the high-water mark, indicating that the COGS inflation or mix shift may be persistent rather than one-off. Net margins similarly fell from 15.8% at the 2026Q2 peak to 10.2% in 2027Q1, a decline that outpaces the gross margin compression and points to operating deleverage on top of cost-of-goods pressure. The pronounced Q1 SG&A seasonality noted in prior analysis amplifies this pattern, but the fact that 2027Q1 operating margin of 13.2% still exceeds the 8.6% of 2025Q1 and 11.1% of 2026Q1 suggests the baseline earning power has improved even as recent quarters disappoint relative to peak.

A 4.0% ROIC against a weighted average cost of capital likely in the 8–10% range suggests Stride may not currently be creating economic value on invested capital, a conclusion that contrasts sharply with peer economics. The erosion from the 7.0% peak appears driven by both margin compression and a declining asset turnover ratio of 0.26, meaning returns are being squeezed from the profitability and efficiency sides simultaneously. Investors should monitor whether the new capex ramp — $78.3M in 2026Q4 and $24.5M in 2027Q1 — eventually lifts asset turnover enough to reverse this trend, or whether the heavier asset base further dilutes returns in the near term.

The deleveraging appears driven primarily by equity accretion from retained earnings — which grew from $558.5M to $1.2B — rather than absolute debt reduction, since total debt actually rose modestly within its $528–619M band. With D/E of 0.37 comparing favorably to Laureate at 0.71 and Adtalem at 0.54, Stride carries meaningfully less balance sheet risk than several capital-intensive education peers. However, given the documented capex ramp and absence of forward guidance, investors should assess whether management intends to deploy this low leverage capacity for acquisitions or organic investment, as either path could alter the current conservative profile.

The DSO expansion from 89 days in 2024Q4 to 109 days in 2027Q1 is the primary driver of the longer CCC, suggesting that state funding disbursements are arriving more slowly or that billing timing has shifted — a pattern that warrants further investigation into the causes behind slower collection cycles. Meanwhile, DPO has remained relatively stable at 9–14 days, meaning Stride is not extracting additional supplier financing to offset the receivables drag. The combination of declining asset turnover and a lengthening cash conversion cycle may partially explain why the company's operating cash conversion has become more volatile, with quarterly OCF/NI ratios swinging from -3.47 to +5.81.